Table 2.
Demographic, Clinical and Neurophysiological Characteristics of Patients
| Mean ± SD | Range | |
|---|---|---|
| Demographic data | N=66 | |
| Male/female | 31/35 | |
| Age, y | 38.62±17.05 | 18–76 |
| Education, y | 12.47±3.41 | 5–18 |
| Clinical characteristics | ||
| Age at onset, y | 19.46±12.13 | – |
| Disease duration, y | 18.98±10.54 | – |
| BMI | 29.95±5.12 | – |
| BMI category (underweight\normal\overweight\obese) |
4\18\24\20 | |
| Neurophysiological data | ||
| MSLT_sl, min | 4.71±3.35 | – |
| SOREMPs, no. | 3.61±1.35 | |
| Biochemical data | ||
| CSFHcrt-1, pg/mL (n = 66) | 56.15±1 | - |
| HLA DQB1*0602 positivity | 66 | |
| Medication used | ||
| Stimulants | 13 | |
| Sodium oxybate | 23 | |
| Antidepressant | 13 | |
| Stimulants plus sodium oxybate | 11 | |
| No medication | 6 |
Note: HLA DQB1*0602 = positivity for human leukocyte antigen.
Abbreviations: BMI, body mass index; MSLT-sl, mean sleep latency at MSLT; SOREMPs, sleep-onset REM periods at MSLT; CSFHcrt-1, cerebrospinal fluid hypocretin-1.